AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
5,162.00
-13.00 (-0.25%)
As of 4:06PM BST. Market open.
Stock chart is not supported by your current browser
Previous Close5,175.00
Open5,182.00
Bid5,162.00 x 6100
Ask5,163.00 x 13000
Day's Range5,161.00 - 5,199.00
52 Week Range3,996.00 - 5,520.00
Volume1,007,308
Avg. Volume2,540,184
Market Cap65.35B
Beta0.63
PE Ratio (TTM)16.93
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.79 (4.51%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
    Zacksyesterday

    AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

    AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

  • Reutersyesterday

    China biotech's 'coming out party' masks long road ahead

    LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (HCM.L), Beigene (BGNE.O) and Zai Lab (ZLAB.O) have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (AZN.L).

  • Financial Times2 days ago

    [$$] Akzo/AstraZeneca: the chemical brothers

    A company incorporating bits of defunct UK multinational Imperial Chemical Industries sends a US suitor packing. Then it spends years coaxing its shares back towards the offer price. It could be AstraZeneca. ...

  • Market Realist2 days ago

    What AstraZeneca’s 3Q17 Performance Tells Us

    AZN stock rose ~0.9% in 3Q17 and has risen ~26.9% YTD (year-to-date) as of October 16.

  • Benzinga2 days ago

    Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

    Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK ). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from ...

  • Reuters2 days ago

    Astra and Merck win speedy review for Lynparza in breast cancer

    U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018. The medicine, which is being jointly developed and marketed with Merck under a deal struck in July, is the first poly ADP-ribose polymerase (PARP) drug to be considered for use outside ovarian cancer. Lynparza is also being tested in prostate and pancreatic cancers, the two companies said on Wednesday.

  • Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
    Zacks4 days ago

    Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

    Foreign markets remain undeterred by discouraging events, notching up weekly gains.

  • Pharma and medtech industries prepare for hard Brexit
    Reuters4 days ago

    Pharma and medtech industries prepare for hard Brexit

    Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc. MeddiQuest, an eight-person consultancy specialising in medical technology regulations, is in the process of moving from outside Cambridge to Ireland. "A significant part of our business is being an authorised EU representative," Chief Executive Neil Armstrong told Reuters.

  • Bloomberg4 days ago

    Drug Companies Fear Brexit Will Hit Medicine Trade

    Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.

  • Cancer Space Update: Lung & Breast Cancer Studies in Focus
    Zacks7 days ago

    Cancer Space Update: Lung & Breast Cancer Studies in Focus

    While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

  • Pfizer weighs $15 bln sale of consumer healthcare business
    Reuters10 days ago

    Pfizer weighs $15 bln sale of consumer healthcare business

    The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.

  • AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
    Zacks11 days ago

    AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

    AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

  • Financial Times11 days ago

    [$$] AstraZeneca chief confident risks will pay off

    Pascal Soriot is the first to recognise that a pharmaceutical company must take risks if it is to find the next transformative medicine. "It would be much simpler to sell toothbrushes and toothpastes ...

  • What's Behind AstraZeneca's September Rebound?
    Motley Fool12 days ago

    What's Behind AstraZeneca's September Rebound?

    AstraZeneca's shares finally broke out of their slump in September.

  • Reuters14 days ago

    FTSE at two-month peak as sterling falters

    British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning groups such as pharma stocks. The FTSE 100 index (.FTSE) closed 0.2 percent up at 7,522.87 points, with Britain's pound on track for its worst week in a year as the Prime Minister hit back at a plot to topple her, saying she would provide "calm leadership" to the country. "The talk of a leadership plot against the Prime Minister is eroding the pound's value and propping up the FTSE 100," CMC Markets analyst David Madden wrote in a note to clients.

  • Drug industry gives up legal battle over new UK cost curbs
    Reuters15 days ago

    Drug industry gives up legal battle over new UK cost curbs

    Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.

  • Tell us how Brexit will work, British companies demand
    Reuters18 days ago

    Tell us how Brexit will work, British companies demand

    British companies including pharmaceuticals giant AstraZeneca urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.

  • Reuters18 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Drugs firm AstraZeneca wants three-year Brexit transition
    Reuters18 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Should You Be Tempted To Buy AstraZeneca PLC (LSE:AZN) At Its Current Price?
    Simply Wall St.21 days ago

    Should You Be Tempted To Buy AstraZeneca PLC (LSE:AZN) At Its Current Price?

    AstraZeneca PLC (LSE:AZN) is trading with a trailing P/E of 21.6x, which is lower than the industry average of 38.5x. While AZN might seem like an attractive stock to buy,Read More...

  • AstraZeneca's Bevespi Improves Lung Function in Phase III Study
    Zacks23 days ago

    AstraZeneca's Bevespi Improves Lung Function in Phase III Study

    AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.

  • 3 High-Yield Stocks for Aggressive Investors
    Motley Fool25 days ago

    3 High-Yield Stocks for Aggressive Investors

    This drugmaker, telecom, and energy company all sport sky-high yields.

  • 12 Flu Season Facts You Need to Know
    Motley Fool26 days ago

    12 Flu Season Facts You Need to Know

    Here's everything you've ever wanted to know about influenza and flu vaccines.

  • AstraZeneca Stock Upgraded: What You Need to Know
    Motley Fool28 days ago

    AstraZeneca Stock Upgraded: What You Need to Know

    Bernstein sees opportunity in a buyout target.